Comparative Pharmacology
Head-to-head clinical analysis: ANCOBON versus NYSTOP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANCOBON versus NYSTOP.
ANCOBON vs NYSTOP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Flucytosine is converted intracellularly to 5-fluorouracil, which inhibits fungal RNA and DNA synthesis by incorporating into RNA and inhibiting thymidylate synthase.
Nystatin binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular ions and cell death.
50-150 mg/kg/day orally divided every 6 hours; intravenous dosing: 50-150 mg/kg/day divided every 12 hours.
Apply a thin layer to affected area 2-3 times daily or as directed. Nystatin is not absorbed systemically; topical use only.
None Documented
None Documented
Terminal elimination half-life 2.5-6 hours (normal renal function). Prolonged to 30-250 hours in renal impairment (CrCl < 20 mL/min). Half-life correlates with creatinine clearance.
Not applicable for systemic pharmacokinetics due to minimal absorption; local half-life on mucosal surfaces is not defined. For intravenous administration (not approved), the terminal half-life is approximately 2-4 hours, but this route is not clinically used.
Primarily renal excretion of unchanged drug (75-90% within 24 hours). Less than 1% eliminated as 5-fluorouracil metabolite. Biliary/fecal excretion negligible.
Nystatin is not absorbed from the gastrointestinal tract or intact skin/mucous membranes; when administered topically or orally, it is excreted almost entirely in feces as unchanged drug (>99%). Less than 1% is excreted renally if ingested. No quantified biliary excretion reported.
Category C
Category C
Antifungal
Antifungal